COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current e...

Full description

Bibliographic Details
Main Authors: Chiara Agrati, Serena Di Cosimo, Daniela Fenoglio, Giovanni Apolone, Fabio Ciceri, Gennaro Ciliberto, Fausto Baldanti, Massimo Costantini, Diana Giannarelli, Giuseppe Ippolito, Franco Locatelli, Alberto Mantovani, Aldo Morrone, Fabrizio Tagliavini, Antonio Uccelli, Pier Luigi Zinzani, Nicola Silvestris, Maria Rescigno
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
vaccine
cancer
immunocompromised
COVID-19
myasthenia
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.704110/full
Description
Summary:Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.
ISSN:1664-3224

Similar Items